Almirall (Seller)AstraZeneca (Buyer)
AstraZeneca will purchase rights to Almirall's respiratory disease business for $875 million up front and up to $1.2 billion in milestones
Almirall (Licensor)Forest Laboratories (Licensee)
Almirall granted Forest rights to develop and commercialize Almirall's LAS100977 in the U.S.
Set Email Alert